iOmx Therapeutics announces discovery of novel, druggable immune-checkpoint targets30. September 2019|In Portfolio News|By eazee-designstudioiOmx Therapeutics announced today the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the company’s proprietary, high-throughput genetic screening platform, iOTarg™. iOTarg is designed to broadly screen tumor cells for hijacked immune checkpoints, which enable targeting of the tumor´s immune resistance mechanisms. PrevNext
